CY1118091T1 - Ανοσολογικως χρησιμα αλατα αργινινης - Google Patents

Ανοσολογικως χρησιμα αλατα αργινινης

Info

Publication number
CY1118091T1
CY1118091T1 CY20161101006T CY161101006T CY1118091T1 CY 1118091 T1 CY1118091 T1 CY 1118091T1 CY 20161101006 T CY20161101006 T CY 20161101006T CY 161101006 T CY161101006 T CY 161101006T CY 1118091 T1 CY1118091 T1 CY 1118091T1
Authority
CY
Cyprus
Prior art keywords
immunology
useful
arginine salts
arginine
salts
Prior art date
Application number
CY20161101006T
Other languages
English (en)
Inventor
Stephanie Kay Dodd
Siddartha Jain
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1118091T1 publication Critical patent/CY1118091T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση ανήκει στο πεδίο των μορφών άλατος μιας ανοσοενισχυτικής ένωσης και την διαμόρφωσή τους για in vivo χρήση.
CY20161101006T 2012-03-07 2016-10-10 Ανοσολογικως χρησιμα αλατα αργινινης CY1118091T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (1)

Publication Number Publication Date
CY1118091T1 true CY1118091T1 (el) 2017-06-28

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101006T CY1118091T1 (el) 2012-03-07 2016-10-10 Ανοσολογικως χρησιμα αλατα αργινινης

Country Status (18)

Country Link
US (1) US9320748B2 (el)
EP (1) EP2822947B1 (el)
JP (1) JP6325986B2 (el)
CN (1) CN104203946B (el)
AU (1) AU2013229466A1 (el)
CA (1) CA2865759C (el)
CY (1) CY1118091T1 (el)
DK (1) DK2822947T3 (el)
ES (1) ES2597755T3 (el)
HR (1) HRP20161354T1 (el)
HU (1) HUE030175T2 (el)
LT (1) LT2822947T (el)
MX (1) MX346678B (el)
PL (1) PL2822947T3 (el)
PT (1) PT2822947T (el)
RU (1) RU2014140336A (el)
SI (1) SI2822947T1 (el)
WO (1) WO2013131985A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JP2013538217A (ja) 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および/またはアジュバントを有する混合ワクチン
CN104159602B (zh) 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
SI3122378T1 (sl) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals S.A. Mutantni stafilokokni antigeni
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
JP3368902B2 (ja) 1992-03-02 2003-01-20 カイロン エセ.ピー.アー. ワクチンおよび診断に有用なHelicobacterpyloriタンパク質
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
JPH10502365A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US20040005667A1 (en) 2000-07-03 2004-01-08 Giuloi Ratti Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
ATE406912T1 (de) 2001-12-12 2008-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
PT2353608T (pt) 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
RU2352356C2 (ru) 2003-06-26 2009-04-20 Новартис Вэксинес Энд Дайэгностикс, Инк. ИММУНОГЕННАЯ КОМПОЗИЦИЯ НА ОСНОВЕ АНТИГЕНА Chlamydia trachomatis (ВАРИАНТЫ) И ЕЕ ИСПОЛЬЗОВАНИЕ
BRPI0508365A (pt) 2004-03-02 2007-07-24 Chiron Corp composições imunogênicas para chlamydia pneumoniae
CN101180312A (zh) 2005-02-18 2008-05-14 诺华疫苗和诊断公司 来自尿路病原性大肠杆菌的免疫原
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
KR20080024125A (ko) 2005-05-12 2008-03-17 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 클라미디아 트라코마티스에 대한 면역원성 조성물
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1976557A2 (en) 2005-12-22 2008-10-08 Novartis Vaccines and Diagnostics S.r.l. Chlamydial antigens
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
CN101951949B (zh) 2007-10-19 2013-10-02 诺华股份有限公司 脑膜炎球菌疫苗制剂
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
CN102481354A (zh) 2009-06-01 2012-05-30 诺华有限公司 肺炎球菌RrgB分化枝的组合物
WO2010144734A1 (en) * 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
JP2013538217A (ja) 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
CA2847204A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens

Also Published As

Publication number Publication date
HUE030175T2 (en) 2017-04-28
US9320748B2 (en) 2016-04-26
CA2865759A1 (en) 2013-09-12
MX2014010423A (es) 2014-09-22
HRP20161354T1 (hr) 2016-12-02
ES2597755T3 (es) 2017-01-20
PT2822947T (pt) 2016-09-26
US20150125475A1 (en) 2015-05-07
MX346678B (es) 2017-03-29
DK2822947T3 (en) 2016-09-19
CA2865759C (en) 2020-07-21
RU2014140336A (ru) 2016-04-27
CN104203946A (zh) 2014-12-10
PL2822947T3 (pl) 2017-01-31
LT2822947T (lt) 2016-10-10
JP6325986B2 (ja) 2018-05-16
AU2013229466A1 (en) 2014-09-04
CN104203946B (zh) 2017-03-22
JP2015511957A (ja) 2015-04-23
SI2822947T1 (sl) 2016-10-28
WO2013131985A1 (en) 2013-09-12
EP2822947B1 (en) 2016-08-03
EP2822947A1 (en) 2015-01-14

Similar Documents

Publication Publication Date Title
CY1118091T1 (el) Ανοσολογικως χρησιμα αλατα αργινινης
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1122222T1 (el) Συνθεση βορονικων αλατων και χρησεις αυτων
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CR20150507A (es) Inhibidores de histona desmetilasas
BR112013023241A2 (pt) melhorias para entidades biológicas imobilizadas
CO7151511A2 (es) Derivado de cicloalcano
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
BR112013029785A2 (pt) dispositivo de varredura para interferometria de coerência baixa
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
UY34343A (es) Proteinas de unión al antígeno cd27l
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
UY34406A (es) Compuestos y métodos para mejorar la respuesta inmune innata
TWD158887S (zh) 粉餅盒
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112015012907A2 (pt) composição de cuidado pessoal
BR112015029858A2 (pt) toalha sanitária
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
CR20120517A (es) Piridinas sustituidas que tienen acción herbicida
CO7350653A2 (es) Retinoides y uso de los mismos
EA201201667A1 (ru) Способ получения l-аргининовой соли периндоприла
FR3005367B1 (fr) Detecteur compact de presence humaine
BR112015024351A2 (pt) formulação de l-5-metiltetrahidrofolato de cálcio amorfo (l-5-mthf-ca)
UY34005A (es) Gen insecticida variante de axmi115 y métodos para utilizarlo
BR112014000256A2 (pt) formulação de microemulsões transparentes e nutritivas